U.S. FDA recommends pause of Johnson & Johnson vaccine after 6 patients develop blood clots

National Coronavirus Coverage

WASHINGTON (WGHP/WJHL) — U.S. government-run vaccine sites are expected to stop offering the Johnson & Johnson coronavirus vaccine after multiple people developed blood clots, according to the New York Times.

The Food and Drug Administration made the announcement Tuesday after six people in the U.S. developed blood clots within two weeks of getting the vaccine. The Centers for Disease Control and FDA are working to determine if there is a link between the vaccine and the blood clots.

“Right now, these adverse event appear to be extremely rare,” the FDA said in a post on Twitter.

Until these agencies can determine the risk, all vaccine providers are under recommendation to pause the use of the Johnson & Johnson vaccine. However, the FDA and CDC are not requiring them to stop.

The FDA said in a tweet that the CDC would convene a meeting on Wednesday to review cases.

“Until that process is complete, we are recommending this pause,” FDA tweeted.

The New York Times reports that one woman died from a possibly vaccine-related clot. Another is in critical condition. All six of the patients were woman between ages 18 and 48.

The decision to halt use of the vaccine comes after the U.S. has already used the Johnson & Johnson vaccine on more than 6.8 million people, according to the FDA.

News Channel 11 has reached out to state and regional health departments to see what impact the pause will have on local events.

Sullivan County Health Department Emergency Response Coordinator Mark Moody said county health officials are working to formulate a plan regarding the FDA’s announcement.

A public information officer from the Virginia Department of Health said a statement will be released soon on plans for vaccination events using the vaccine.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending Stories

Don't Miss

More Don't Miss